The United States Patent and Trademark Office (USPTO) has granted patent US12582640B2 to Vanda Pharmaceuticals Inc. This patent covers a method for treating lower respiratory tract infections, specifically mentioning those caused by coronaviruses (like COVID-19) and influenza, utilizing tradipitant, an NK-1 receptor antagonist. The patent was filed on March 24, 2021, and granted on March 24, 2026, with 20 claims.

This patent grant is primarily an intellectual property matter for Vanda Pharmaceuticals. While it signifies a new therapeutic application for tradipitant, it does not impose immediate compliance obligations on other entities. However, it may influence future market exclusivity and competitive landscape for respiratory infection treatments. Companies operating in the pharmaceutical sector, particularly those involved with respiratory treatments or NK-1 receptor antagonists, should be aware of this granted patent for competitive intelligence and potential licensing considerations.